References

1.Fryers G. in New Perspectives on aspirin therapy,1982 Aspirin Foundation Symposium, New Orleans, April 21-3 1982.

2.Pierpoint WS. The natural history of salicylic acid, plant product and mammalian medicine. Interdisciplinary Science Reviews 1997;22:45-52.

3.Stone E. An account of the success of the bark of the willow in the cure of agues. Philos.Trans. 1763;53:195-200.

4.Friend D. aspirin: the unique drug. Arch.Surg. 1974;108:765-9.

5.Kroneberg HG. Historical remarks on acetyl salicylic acid. in Lee M (ed.) 1982 Seoul International aspirin Symposium Proceedings, 5-17.

6.GrossM, Greenberg LA. The Salicylates: a critical bibliographic review. Conn. Hillhouse Press, 1948.

7.Briard C. Anniversaire en 1997 Felix Hoffman decouvre l’aspirine. Le Moniteur 1997;2198:36-8.

8.Wilthauer J, Wohlgemut J. Uber aspirine (acetylsalicylsaure). Ther.Mh. (Halbmh) 1899;13:276.

9.Donne A. De l’origine des globules du sang, deleur mode de formation et de leur fin. Compt.Rend.Acad.Sc. 1842;14:366-8.

10.Osler W. An account of certain organisms occuring in the liquor sanguinis. Proc.R.Soc.Lond. 1874;5:692-734.

11.Haerem JW. Platelet aggregates and mural microthrombin in the early stages of acute phase of coronary disease. Thromb.Res. 1974;5:243.

12.Davies MJ, Thomas AC. Thrombosis and acute coronary-artery lesions in sudden cardiac ischaemic death. N.Eng.J.Med. 1984;10:1137-40.

13.Bensaulde R, River L. Les formes chroniques du pirpura hemerragique. Arch.Gen. de Med. 1905, Janvier.

14.O’Brien JR. Platelet aggregation Part II. Some results from a new method of study. J.Clin.Path. 1962;15:452-5.

15.Born GVR. Aggregation of blood platelets by adenosine diphosphate and it’s reversal. Nature 1962;194:927-9.

16.O’Brien JR. The adhesivness of native platelets and it’s prevention. J.Clin.Path. 1961;14:140-9.

17.O’Brien JR. The adhesiveness of native platelets: some anti-adhesive drugs and their mode of action. Proc.VIII Congress Europ.Soc.Haem. 1961:51-6.

18.Morris CDW. Acetylsalicylic acid and platelet stickiness. Lancet 1967;I:279-80.

19.O’Brien JR. Effects of salicylates on human platelets. Lancet 1968;I:779-83.

20.Stuart RK. Platelet function studies in human beings receiving 300 mg of aspirin per day. J.Lab.Clin.Med. 1970;75:463-71.

21.Weiss HJ, Aledort LM, Kochwa S. The effect of salicylates in the hemostatic properties of platelets in man. J.Clin.Invest. 1968;47:2169-80.

22.Craven LL. Acetyl salicylic acid: possible prevention of coronary thrombosis. Annals of Western Medicine and Surgery 1950;4:95-9.

23.Craven LL. Experiences with aspirin in the non-specific prophylaxis of coronary thrombosis. Mississippi Valley Med.J. 1953;75:38-44.

24.Craven LL. Prevention of coronary thrombosis and cerebral thrombosis. Mississippi Valley Med.J. 1956;78:213-5.

25.Elwood PC, Cochrane AL, Burr M, et al. A randomised, controlled trial of acetyl salicylic acid in the secondary prevention of mortality from myocardial infarction. Brit.Med.J. 1974;I:436-40.

26.Coronary Drug Project (CDP). aspirin in coronary heart disease. J.Chron.Dis. 1976;29:625-42.

27.Elwood PC, Sweetnam PM. aspirin and secondary mortality after myocardial infarction. Lancet 1979;ii:1313-5.

28.Breddin K, Loew D, Lechner K et al. Secondary prevention of myocardial infarction:a comparison of aceytl salicylic acid, placebo and phenproumen. Haemostasis 1980;9:325-44.

29.aspirin Myocardial Infarction Study Research Group. (AMIS) A randomised controlled trial in persons recovered from myocardial infarction. JAMA 1980;243:661-69.

30.Persantine-aspirin Re-infarction study (PARIS) group. Persantine and aspirin in coronary heart disease. Circulation 1980;62:449-61.

31.Editorial. aspirin after myocardial infarction. Lancet 1980;I:1172-3.

32.Chalmers I. Improving the quality and dissemination of reviews of clinical research. in: Lock S. (Ed) The future of medical journals: in commemoration of 150 years of the British Medical Journal, London BMJ, 1991.

33.Antiplatelet trialists collaboration. Secondary prevention of vascular disease by prolonged antiplatelet therapy. Brit.Med.J. 1988;296:320-1.

34.Antiplatelet trialists collaboration. Collaborative overview of random trials of anti-platelet therapy - 1. Prevention of death, myocardial infarction and stroke by prolonged anti-platelet therapy in various categories of patients. Brit.Med.J. 1994;308:81-106.

35.Collins R, Peto R, Baigent C et al. aspirin, heparin and fibrinolytic therapy in suspected acute myocardial infarction. N.Eng.J.Med. 1997;336:847-60.

36.MRC Press release: Life-saving aspirin. January 7 1994.

37.Solomon DH, Hart RG. Current opinion. Neurology 1994;7:48-53.

38.Chinese Acute Stroke Trial Collaborative Group (CAST). Chinese Acute Stroke Collaborative Group: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke.Lancet 1997;349:1641-7.

39.The International Stroke Trial (IST) Collaborative Group. The international stroke trial (IST): a randomised trial of aspirin, subcutaneous heparin, both or neither among 19,435 patients with acute ischaemic stroke. Lancet 1997;349:1569-77.

40.Kmietowicz Z. aspirin benefits patients with stroke - but only just. Brit.Med.J. 1997;314:1646.

41.Peto R, Gray R, Collins R et al. Randomised trial of prophylactic daily aspirin in British male doctors. Brit.Med.J. 1988;296:313-6.

42.Steering Committee of the Physicians’ Health Study Research Group. Final report on the aspirin component of the ongoing physicians’ health study. N.Eng.J.Med. 1989;321:129-35.

43.Second International Study of Infarct Survival Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988;ii:349-60.

44.Elwood PC, Williams WO. A randomised controlled trial of aspirin in the prevention of early mortality in myocardial infarction. J.Roy.Coll.Gen.Pract. 1979;29:413-6.

45.Moher M, Moher D, Haevlock P. Survey of whether general practitioners carry aspirin in their doctor’s bag. Brit.Med.J. 1994;308:761-2.

46.Muir N, Nichols JD, Clifford JM, et al. The influence of dosage in aspirin kinetics: implications for acute cardiovascuar use. Curr.Med.Res.Op. 1997;13:547-53.

47.Elwood PC. Correspondence. Lancet 1997;349:872.

48.Fitzgerald DJ, Catella F, Roy L et al. Marked platelet activation in vivo after intravenous strptokinase in patients with acute myocardial infarction. Circulation 1988;77:142-50.

49.Rudd MA, George D, Amarante P et al. Temporal effects of thrombolytic agents on platelet function in vivo and their modulation by prostaglandins. Circ.Res. 1990;67:1175-81.

50.Rasmanis G, Vestequist O, Green K et al. Evidence of increased platelet activation after thrombolysis in patients with acute myocardial infarction. Brit.Heart J. 1992;68:374-6.

51.Anonymous. Which prophylactic aspirin? Drugs & Therapeutic Bulletin 1997;35:7-8.

52(a). Banoob DW, McCloskey WW, Webster W. Risk of gastric injury with enteric- versus nonenteric-coated aspirin. Ann.Pharmacother. 2002;36:163-6.

52(b). Dammann HG, Burkhardt F, Wolf N. Enteric coating of aspirin significantly decreases gastroduodenal mucosal lesions.   Aliment.Pharmacol.Ther. 1999;13:1109-14.

53.Bergentoft C et al. Absorption of acetyl salicylic acid from enteric-coated tablets in relation to gastric emptying and in-vivo disintegration. J.Pharm.Pharmacol. 1984;36:350-1.

54.Kristiansen is, Eggen AE, Thelle DS. Cost effectiveness of incremental programmes for lowering serum cholesterol concentrations: is individual intervention worthwhile? Brit.Med.J. 1991;302:1057-60.

55.Ramsay LE, Yeo WW, Jackson PR. Dietary reduction of serum cholesterol concentration.: time to think again. Brit.Med.J. 1991;303:953-8.

56.Ferner RE, Neil HAW. A suitable case for treatment. Lancet 1995;345:1051.

57.Frishman WH, Burns B, Atac B et al. Novel antiplatelet therapies for the treatment of patients with ischaemic heart disease: inhibitors of the platelet glycoprotein IIb/IIIa integrin inhibitor. American Heart Journal 1995;130:877-92.

58.Moloney BA. An analysis of the side-effects of ticlopodine. in Hass WK, Easton JD (eds) Ticlopodine, platelets and vascular disease. New York, Springer-Verlag, 1993.

59.CAPRIE Steering Committee. A randomised, blinded trial of Clopidogrel versus aspirin in patients at risk if ischaemic events. (CAPRIE) Lancet 1996;348:1329-36.

60.CLASP (Collaborative Low-Dose aspirin Study in Pregnancy) Collabortive Group: a randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. Lancet 1994

61.Gupta SK, Joshi S. Relationship between aldose reductase inhibiting activity and anticataract action of various non-steroidal anti-inflammatory drugs. in Sasaki K, Hockwin O (eds) Distribution of cataracts in the population and influencing factors and developments in ophthalmology. Basl, Karger, 1991.

62.Thun MJ, Namboodirir MM, Heath CW jnr. aspirin use and the reduced risk of fatal colon cancer. N.Eng.J.Med. 1991;325:1593-6.

63.Greenberg ER, Baron JA, Freeman DH jnr. Reduced risk of large-bowel adenomas among aspirin users. The polyp prevention study group. Nat.Cancer Instiy. 1993;85:912-6.

64.Giovannucci E, Egan KM, Hunter D et al. aspirin and the risk of colorectal cancer. N.Eng.J.Med. 1995;333:655-7.

65.Meyer JS, Rogers RL, McClintic K et al. A randomised clinical trial of daily aspirin in multi-infarct dementia. A pilot study. J.Am.Geriat.Soc. 1989;37:549-55.

66.Richards M, Meade TW, Peart S et al. Is there any evidence for a protective effect of anti-thrombotic medication on cognitive function in men at risk of cardiovascular disease? Some preliminary findings. Brit.Med.J. 1997;62:269-72..

67.Stewart WF, Kawas C, Corrada M, Metter EJ. Risk of Alzheimer’s disease and duration of NSAID use. Neurology 1997;48:626-32.

68.Brietner JC, Gau BA, Welsh KA et al. Inverse association of anti-inflammatory treatments and Alzheimer’s disease : initial results of a co-twin control study. Neurology 1994;44:227-32.

69.Ridker PM, Cuchman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflamation, aspirin and the risk of cardiovascular disease in apparently healthy men. NEJM. 1997;336:973-9..